JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model

Experimental Hematology

Volumn 34, Issue 10, 2006, Pages 1385-1392

  Uesato, Naofumi ^a   Fukui, Kenji ^a   Maruhashi, Junji ^a   Tojo, Arinobu ^b   Tajima, Nobuyuki ^a  

^a JAPAN TOBACCO INC   (Japan)

^b THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTILEUKEMIC AGENT; CD45 ANTIGEN; CYTARABINE; CYTOKINE; ETHYL N [3,5 DICHLORO 2 HYDROXY 4 [2 (4 METHYLPIPERAZIN 1 YL)ETHOXY]BENZOYL]PHENYLALANINE; GANGLIOSIDE GM1; GROWTH FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 8; JTE 607; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BLOOD LEVEL; BONE MARROW CELL; CANCER MODEL; CANCER PATIENT; CELL KILLING; CELL PROLIFERATION; CELL STRAIN U937; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DETERIORATION; DRUG EFFECT; DRUG POTENCY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PARACRINE SIGNALING; PRIORITY JOURNAL; RADIATION DOSE; SCID MOUSE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR XENOGRAFT; WHOLE BODY RADIATION;

ANIMALS; ANTIGENS, CD45; AUTOCRINE COMMUNICATION; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INTERLEUKIN-8; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PARACRINE COMMUNICATION; PHENYLALANINE; PIPERAZINES; TRANSPLANTATION, HETEROLOGOUS;

EID: 33748522067     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.05.016     Document Type: Article

References (37)

1. Lowenberg B., Downing J.R., and Burnett A. Acute myeloid leukemia. N Engl J Med 341 (1999) 1051-1062
2. Ohno R., Kobayashi T., Tanimoto M., et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer 71 (1993) 3888-3895
3. Hann I.M., Stevens R.F., Goldstone A.H., et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Blood 89 (1997) 2311-2318
4. Stone R.M. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 52 (2002) 363-371
5. Fiedler W., Graeven U., Ergün S., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89 (1997) 1870-1875
6. Bruserud Ø., Ryningen A., Wergeland L., Glenjen N., and Gjertsen B.T. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 89 (2004) 391-402
7. Ryningen A., Wergeland L., Glenjen N., Gjertsen B.T., and Bruserud Ø. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leuk Res 29 (2005) 185-196
8. Glenjen N., Hatfield K., and Bruserud Ø. Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels. Eur J Haematol 74 (2005) 24-34
9. Oster W., Cicco N.A., Klein H., Hirano T., Kishimoto T., and Lindemann A. Participation of cytokine interleukin 6, tumor necrosis factor-α, and interleukin 1-β secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 84 (1989) 451-457
10. Rogers S.Y., Bradbury D., Kozlowski R., and Russell N.H. Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells. Exp Hematol 22 (1994) 593-598
11. Foss B., Mentzoni L., and Bruserud Ø. Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts. J Hematother Stem Cell Res 10 (2001) 81-93
12. Glenjen N., Hovland R., Wergeland L., Wendelbo O., Ernst P., and Bruserud Ø. The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status. Eur J Haematol 71 (2003) 163-173
13. Vinante F., Rigo A., Vincenzi C., et al. IL-8 mRNA expression and IL-8 production by acute myeloid leukemia cells. Leukemia 7 (1993) 1552-1556
14. Tobler A., Moser B., Dewald B., et al. Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood 82 (1993) 2517-2525
15. Aguayo A., Estey E., Kantarjian H., et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94 (1999) 3717-3721
16. Aguayo A., Kantarjian H., Estey E., et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 95 (2002) 1923-1930
17. Meyers C.A., Albitar M., and Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104 (2005) 788-793
18. de Bont E.S., Vellenga E., Molema G., van Wering E., de Leij L.F., and Kamps W.A. A possible role for spontaneous interleukin-8 production by acute myeloid leukemia cells in angiogenesis related process: work in progress. Med Pediatr Oncol 37 (2001) 511-517
19. Padro T., Ruiz S., Bieker R., et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95 (2000) 2637-2644
20. Komorowski J, Jerczyńska H, Siejka A, et-al. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci. In press.
21. Rosiñol L., Cibeira M.T., Segarra M., et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine 26 (2004) 145-148
22. Zorat F., Shetty V., Dutt D., et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 115 (2001) 881-894
23. Greenberg P. Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines. Ann Rheum Dis 60 (2001) iii41-iii42
24. Steins M.B., Padro T., Bieker R., et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 99 (2002) 834-839
25. Kakutani M., Takeuchi K., Waga I., Iwamura H., and Wakitani K. JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res 48 (1999) 461-468
26. Iwamura H., Sato M., and Wakitani K. Comparative study of glucocorticoids, cyclosporine A, and JTE-607 [(-)-Ethyl-N[3,5-dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl]-L-phenylalaninate dihydrochloride] in a mouse septic shock model. J Pharmacol Exp Ther 311 (2004) 1256-1263
27. Sasaki J., Fujishima S., Iwamura H., Wakitani K., Aiso S., and Aikawa N. Prior burn insult induces lethal acute lung injury in endotoxemic mice: effects of cytokine inhibition. Am J Physiol Lung Cell Mol Physiol 284 (2003) 270-278
28. Sasakawa Y., Naoe Y., Inoue T., et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 64 (2002) 1079-1090
29. Matsunaga T., Takemoto N., Sato T., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9 (2003) 1158-1165
30. Sugiyama H., Inoue K., Yamagami T., Soma T., Miyake S., and Hirata M. The expression of IL-6 and its related genes in acute leukemia. Leuk Lymphoma 21 (1996) 49-52
31. Russell N.H. Autocrine growth factors and leukaemic haemopoiesis. Blood Rev 6 (1992) 149-156
32. Oster W., Lindermann A., Horn S., Mertelsmann R., and Herrmann F. TNF-α but not TNF-β induces secretion of colony-stimulation factor for macrophages (CSF-1) by human monocytes. Blood 70 (1987) 1700-1703
33. Munker R., Gasson J., Ogawa M., and Koeffler H.P. Reconbinant human TNF induces production of granulocyte-monocyte colony-stimulation factor. Nature 323 (1986) 79-83
34. de Bont E.S., Rosati S., Jacobs S., Kamps W.A., and Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 113 (2001) 296-304
35. Hsu H.C., Lee Y.M., Tsai W.H., et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology 63 (2002) 64-69
36. Dumitru C.D., Ceci J.D., Tsatsanis C., et al. TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103 (2000) 1071-1083
37. Kooijman R., Coppens A., and Hooghe-Peters E. IGF-I stimulates IL-8 production in the promyelocytic cell line HL-60 through activation of extracellular signal-regulated protein kinase. Cell Signal 15 (2003) 1091-1098